<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03224780</url>
  </required_header>
  <id_info>
    <org_study_id>Beni-Suef 13</org_study_id>
    <nct_id>NCT03224780</nct_id>
  </id_info>
  <brief_title>Creatine Kinase Versus 3D Doppler for Antenatal Diagnosis of Abnormal Adherent Placenta.</brief_title>
  <official_title>Creatine Kinase Versus 3D Doppler for Antenatal Diagnosis of Morbidly Adherent Placenta</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beni-Suef University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beni-Suef University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Placenta accreta is a potentially life-threatening obstetric condition that requires a&#xD;
      multidisciplinary approach to management.Diagnosis of placenta accreta before delivery&#xD;
      minimizes potential maternal or neonatal morbidity and mortality. In this study the&#xD;
      researchers will evaluate the role and cost effectiveness of biochemical marker as creatine&#xD;
      kinase in comparison with 3D Doppler ultrasound in antenatal diagnosis of placenta accreta&#xD;
      and its variants in patients with placenta previa totalis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Abnormal placentation poses a diagnostic and treatment challenge for all providers caring for&#xD;
      pregnant women. As one of the leading causes of postpartum hemorrhage, abnormal placentation&#xD;
      involves the attachment of placental villi directly to the myometrium with potentially deeper&#xD;
      invasion into the uterine wall or surrounding organs. Surgical procedures that disrupt the&#xD;
      integrity of uterus, including cesarean section, dilatation and curettage, and myomectomy,&#xD;
      have been implicated as key risk factors for placenta accreta(Megier et al., 2000).Prenatal&#xD;
      diagnoses of placenta accreta through the use of gray-scale ultrasonography, color Doppler&#xD;
      imaging, and magnetic resonance imaging have been reported previously (Chou et al., 1997).&#xD;
&#xD;
      Placenta increta and percreta have rarely been diagnosed antepartum, and ultrasonographic&#xD;
      findings may provide the only objective evidence of placenta accreta.A biochemical marker for&#xD;
      this condition would therefore be useful (Ophir et al., 1999).It is critical to make the&#xD;
      diagnosis before delivery because preoperative planning can significantly decrease blood loss&#xD;
      and avoid substantial morbidity associated with placenta accreta (Shih et al., 2009).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2017</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>maternal morbidity</measure>
    <time_frame>from 28 weeks gestation until 24 hours postpartum.</time_frame>
    <description>Antepartum and Postpartum maternal complications of morbidly adherent placenta.</description>
  </primary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Placenta Accreta</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>maternal serum creatine kinase</intervention_name>
    <description>Biochemical marker</description>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>3D Doppler ultrasound</intervention_name>
    <description>Doppler for placental vessels</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        pregnant women with persistent placenta previa (after 28 weeks' gestation) were&#xD;
        prospectively enrolled into this study.complete imaging using all diagnostic techniques&#xD;
        (gray-scale, color Doppler and 3D power Doppler), and full availability of delivery&#xD;
        information. Ultrasound examination was performed using a 3D ultrasound system equipped&#xD;
        with a 4-8-MHz transabdominal transducer .â€¢ Serum Creatine kinase assessement (reference&#xD;
        range is 25-160 U/L).(Ophir et al 1999)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - a- Pregnant lady with history of previous cesarean section or hysterotomy. b- Placenta&#xD;
        previa with its lower edge covering the scar of previous cesarean section as diagnosed by&#xD;
        2DU/S.&#xD;
&#xD;
        c- Gestational age ranging from 28 wks - Full term.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women with one or more of the following conditions contributing to rhabdomyolysis:&#xD;
&#xD;
               1. Crush injury and prolonged surgery.&#xD;
&#xD;
               2. Embolism, thrombosis, D.V.T., myocardial or brain infarction.&#xD;
&#xD;
               3. Drug overdose: Antipsychotics, antidepressants, hypnotics, narcotics, alcohol,&#xD;
                  halothane,salicylates.&#xD;
&#xD;
               4. Excessive muscle activity as epileptic fit.&#xD;
&#xD;
               5. Chronic hypertension &amp; PIH&#xD;
&#xD;
               6. Endocrine disorders: hyper-/hypothyroidism, and diabetes mellitus,history of&#xD;
                  liver disease or renal disease.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Nesreen A Shehata</last_name>
    <phone>00201024150605</phone>
    <phone_ext>02</phone_ext>
    <email>nesoomar@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hamada Ashry Abd el Wahed</last_name>
    <phone>01007240754</phone>
    <phone_ext>02</phone_ext>
    <email>hamadaashry2010@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beni-Suef University</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nesreen A Shehata, MD</last_name>
      <phone>00201024150605</phone>
      <phone_ext>02</phone_ext>
      <email>nesoomar@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Hamada A Abdel wahed, MD</last_name>
      <phone>01007240754</phone>
      <phone_ext>02</phone_ext>
      <email>hamadaashry2010@yahoo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Nesreen A Shehata, assistant prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Chou MM, Ho ES. Prenatal diagnosis of placenta previa accreta with power amplitude ultrasonic angiography. Am J Obstet Gynecol. 1997 Dec;177(6):1523-5.</citation>
    <PMID>9423762</PMID>
  </reference>
  <reference>
    <citation>Megier P, Harmas A, Mesnard L, Esperandieu OL, Desroches A. Picture of the month. Antenatal diagnosis of placenta percreta using gray-scale ultrasonography, color and pulsed Doppler imaging. Ultrasound Obstet Gynecol. 2000 Mar;15(3):268.</citation>
    <PMID>10846790</PMID>
  </reference>
  <reference>
    <citation>Ophir E, Tendler R, Odeh M, Khouri S, Oettinger M. Creatine kinase as a biochemical marker in diagnosis of placenta increta and percreta. Am J Obstet Gynecol. 1999 Apr;180(4):1039-40.</citation>
    <PMID>10203680</PMID>
  </reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>July 19, 2017</study_first_submitted>
  <study_first_submitted_qc>July 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2017</study_first_posted>
  <last_update_submitted>January 30, 2021</last_update_submitted>
  <last_update_submitted_qc>January 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beni-Suef University</investigator_affiliation>
    <investigator_full_name>Nesreen Abdel Fattah Abdullah Shehata</investigator_full_name>
    <investigator_title>Assistant Professor of Obstetrics and Gynecology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Placenta Accreta</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

